{"id":"formoterol-aldo","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Muscle cramps"},{"rate":"1-5","effect":"Nervousness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP and leads to smooth muscle relaxation and airway dilation. Its long-acting formulation provides sustained bronchodilation for 12 hours or more, making it suitable for maintenance therapy in chronic obstructive airway diseases. It is commonly combined with inhaled corticosteroids for enhanced anti-inflammatory and bronchodilatory effects.","oneSentence":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:54.778Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma (maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT06282861","phase":"PHASE4","title":"ANTES B+ Clinical Trial","status":"TERMINATED","sponsor":"Fundacio Privada Mon Clinic Barcelona","startDate":"2024-02-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"DRUG INTERACTION"},{"count":5,"reaction":"NEUROLEPTIC MALIGNANT SYNDROME"},{"count":5,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"RESTING TREMOR"},{"count":2,"reaction":"RESTLESSNESS"},{"count":1,"reaction":"HEPATITIS CHOLESTATIC"},{"count":1,"reaction":"POSTURAL TREMOR"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LABA"],"phase":"marketed","status":"active","brandName":"Formoterol Aldo","genericName":"Formoterol Aldo","companyName":"Fundacio Privada Mon Clinic Barcelona","companyId":"fundacio-privada-mon-clinic-barcelona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}